Mitsui Chemicals outlines rationale and targets for JSR acquisition

Key highlights
  • Mitsui Chemicals expects FY2030 operating income before special items to exceed ¥300 billion across its specialty and polymer science businesses.
  • The FY2030 ICT operating income target is more than ¥190 billion, including JSR, existing businesses and synergies.
  • Interest expenses are expected to reach about ¥60 billion in FY2029 or FY2030; permanent financing is targeted within approximately one year of closing.
  • Equity financing of up to ¥150 billion is under consideration, alongside divestitures and other funding options.

Strategic rationale

Mitsui Chemicals says acquiring JSR will accelerate its portfolio transformation and strengthen ICT, particularly semiconductor materials. It cited complementary product portfolios and JSR’s position as the No. 2 company in the global photoresist market. The companies plan to combine high-growth ICT with stable-growth Life & Healthcare in a global specialty business, while B&GM and Mobility will form a polymer science business.

Synergies and integration

Expected benefits include joint development and customer access, with products such as JSR resists and Mitsui Chemicals’ EUV pellicles developed and proposed as part of an integrated lithography process. The companies will also assess efficiencies across sites, outsourced functions, supply chains, logistics and overlapping R&D. Mitsui Chemicals cited the proximity of JSR’s Yokkaichi R&D site and its Nagoya site as an opportunity for researcher collaboration and shared facility use.

Financial outlook

For FY2030, Mitsui Chemicals targets more than ¥300 billion in combined operating income before special items, including more than ¥190 billion from ICT. It expects net income attributable to owners of the parent of about ¥150 billion. Interest expenses are expected to reach approximately ¥60 billion in FY2029 or FY2030. Bridge financing is planned at closing, with a transition to permanent financing targeted within about one year. Equity financing of up to ¥150 billion is under consideration.

Approvals

The company does not expect the combination to significantly increase market share in any product, but acknowledges that antitrust reviews may take longer than anticipated and says it will respond to information requests from relevant authorities.

Source: Mitsui Chemicals

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

11 November 2026
Mitsui Chemicals lifts FY2026 forecast after first-half profit growth

The company reported stronger results across most segments and outlined a ¥1.84 trillion agreement to acquire JSR, subject to regulatory approvals.

9 November 2026
Mitsui Chemicals to acquire JSR for major portfolio transformation

Plans to build a global specialty semiconductor-materials platform, target operating income ≥¥300bn, EV ~¥1.392tn with ¥447.9bn debt assumed, DBJ to invest ¥200bn in preferred shares; closing H2 FY27.

9 November 2026
Mitsui Chemicals to acquire JSR, file shelf registration and revise B&GM split-off scope

Plans to buy JSR for ¥1.84 trillion, target closing in H2 of FY ending March 2028; DBJ to co-invest ¥200bn; shelf registration up to ¥150bn to help refinance a ¥1,640bn bridge loan.